Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ACP 01

Next Previous
Drug Profile

ACP 01

Alternative Names: ACP-01; Angiogenic Cell Precursors - Hemostemix; Endothelial progenitor cells - Hemostemix; VesCell

Latest Information Update: 12 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hemostemix
  • Developer Hemostemix; TheraVitae
  • Class Anti-inflammatories; Anti-ischaemics; Cardiovascular therapies; Heart failure therapies; Ischaemic heart disorder therapies; Stem cell therapies; Vascular disorder therapies
  • Mechanism of Action Angiogenesis inducing agents; Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Chronic limb-threatening ischemia; Wounds
  • Phase II Angina pectoris; Cardiomyopathies; Dilated cardiomyopathy; Peripheral arterial disorders
  • Phase I Ischaemia; Vascular dementia
  • Discontinued Heart failure; Thromboangiitis obliterans

Most Recent Events

  • 12 Nov 2025 Phase-I clinical trials in Ischaemia (Parenteral), prior to November 2025 (Hemostemmix pipeline, November 2025)
  • 12 Nov 2025 Phase-I clinical trials in Vascular dementia (Parenteral), prior to November 2025 (Hemostemmix pipeline, November 2025)
  • 12 Nov 2025 Phase-II clinical trials in Angina pectoris (Parenteral), prior to November 2025 (Hemostemmix pipeline, November 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top